Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday

Inozyme Pharma (NASDAQ:INZY) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Inozyme Pharma to post earnings of ($0.43) per share for the quarter.

Inozyme Pharma Stock Up 33.9 %

Inozyme Pharma stock opened at $1.62 on Friday. The company has a market capitalization of $104.07 million, a PE ratio of -1.04 and a beta of 1.39. Inozyme Pharma has a 12-month low of $0.72 and a 12-month high of $6.24. The firm’s fifty day moving average is $1.01 and its 200 day moving average is $2.11. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Wedbush reiterated an “outperform” rating and issued a $7.00 price target (down previously from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. Piper Sandler decreased their price objective on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Raymond James cut their target price on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Inozyme Pharma in a research note on Thursday, April 10th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $14.63.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.